Unknown PHASE2 INTERVENTIONAL 2-arm NCT04026984

Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years

Double Blind, Multi-center Study to Evaluate the Safety and Efficacy of 100 mg Twice Daily Rifamycin SV MMX® Added to Standard ORT Versus Placebo Plus ORT, in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years

Sponsor: RedHill Biopharma Limited

Conditions Traveler's Diarrhea

Interventions Placebo Rifamycin SV-MMX

Updated 9 times since 2019 Last updated: Jan 26, 2023 Started: Jun 30, 2024 Primary completion: Jun 30, 2025 Completion: Dec 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Traveler's Diarrhea and is currently ongoing. RedHill Biopharma Limited leads this study, which shows 9 recorded versions since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Feb 2026 — Present [monthly]

Unknown PHASE2

Status: Not Yet Recruiting → Unknown
Sep 2024 — Feb 2026 [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
Feb 2023 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2
May 2022 — Feb 2023 [monthly]

Not Yet Recruiting PHASE2

▶ Show 4 earlier versions

Feb 2021 — May 2022 [monthly]

Not Yet Recruiting PHASE2
Jan 2021 — Feb 2021 [monthly]

Not Yet Recruiting PHASE2
Dec 2019 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2
Aug 2019 — Dec 2019 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

RedHill Biopharma Limited

Data source: RedHill Biopharma Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.